Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Aβ42 production

Nature Medicine

Volumn 11, Issue 5, 2005, Pages 545-550

  Kukar, Thomas ^a   Murphy, Michael Paul ^a,c   Eriksen, Jason L ^a   Sagi, Sarah A ^b   Weggen, Sascha ^b,d   Smith, Tawnya E ^a   Ladd, Thomas ^a   Khan, Murad A ^a   Kache, Rajashaker ^a   Beard, Jenny ^a   Dodson, Mark ^a   Merit, Sami ^a   Ozols, Victor V ^a   Anastasiadis, Panos Z ^a   Das, Pritam ^a   Fauq, Abdul ^a   Koo, Edward H ^b   Golde, Todd E ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; 6 (2,4 DIFLUOROPHENYLTHIO) 5 METHANESULFONAMIDO 1 INDANONE; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; ANTILIPEMIC AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ETORICOXIB; FARNESYL DIPHOSPHATE; FENOFIBRATE; FT 1; GAMMA SECRETASE; GERANYLGERANYL PYROPHOSPHATE; INDOMETACIN; INDOMETACIN DERIVATIVE; ISOPRENOID; LM 4114; LM 4414; LUMIRACOXIB; MECLOFENAMIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PRESENILIN DERIVATIVE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; ROFECOXIB; S 2474; TILMACOXIB; UNCLASSIFIED DRUG; VALDECOXIB;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID PRECURSOR PROTEIN SECRETASES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTILIPEMIC AGENTS; ASPARTIC ENDOPEPTIDASES; BRAIN; CELL LINE; CYCLOOXYGENASE INHIBITORS; ENDOPEPTIDASES; ENZYME ACTIVATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOPRECIPITATION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MASS SPECTROMETRY; PROCETOFEN; PROTEIN-SERINE-THREONINE KINASES; PYRAZOLES; RHOA GTP-BINDING PROTEIN; SULFONAMIDES; TRANSFECTION;

ANIMALIA;

EID: 21044458540     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1235     Document Type: Article

References (48)

1. Selkoe, D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81, 741-766 (2001).
2. Golde, T.E., Eckman, C.B. & Younkin, S.G. Biochemical detection of Abeta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease. Biochim. Biophys. Acta 1502, 172-187 (2000).
3. Younkin, S.G. The role of A beta 42 in Alzheimer's disease. J. Physiol. Paris 92, 289-292 (1998).
4. Scheuner, D. et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 2, 864-870 (1996).
5. Duff, K. et al. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature 383, 710-713 (1996).
6. Iijima, K. et al. Dissecting the pathological effects of human Abeta40 and Abeta42 in Drosophila: a potential model for Alzheimer's disease. Proc. Natl. Acad. Sci. USA 101, 6623-6628 (2004).
7. McGowan, E. et al. Selective Overexpression of Abeta42, but not Abeta40, in the secretory pathway is sufficient for plaque deposition in mice. Abstr. Soc. Neurosci. 877.14 (2003).
8. Eriksen, J.L. et al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J. Clin. Invest. 112, 440-449 (2003).
9. Weggen, S. et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414, 212-216 (2001).
10. Weggen, S. et al. Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity. J. Biol. Chem. 278, 31831-31837 (2003).
11. Sagi, S.A., Weggen, S., Eriksen, J., Golde, T.E. & Koo, E.H. The non-cyclooxygenase targets of non-steroidal anti-inflammatory drugs, lipoxygenases, peroxisome proliferator-activated receptor, inhibitor of kappa B kinase, and NF kappa B, do not reduce amyloid beta 42 production. J. Biol. Chem. 278, 31825-31830 (2003).
12. Takahashi, Y. et al. Sulindac sulfide is a noncompetitive gamma-secretase inhibitor that preferentially reduces Abeta 42 generation. J. Biol. Chem. 278, 18664-18670 (2003).
13. Beher, D. et al. Selected non-steroidal anti-inflammatory drugs and their derivatives target gamma -secretase at a novel site-evidence for an allosteric mechanism. J. Biol. Chem. 279, 43419-43426 (2004).
14. Lleo, A. et al. Nonsteroidal anti-inflammatory drugs lower Abeta42 and change presenilin 1 conformation. Nat. Med. 10, 1065-1066 (2004).
15. Gebel, T., Arand, M. & Oesch, F. Induction of the peroxisome proliferator activated receptor by fenofibrate in rat liver. FEBS Lett. 309, 37-40 (1992).
16. Kalgutkar, A.S., Marnett, A.B., Crews, B.C., Remmel, P.P. & Marnett, L.J. Ester and amide derivatives of the nonsteroidal antiinflammatory drug, indomethacin, as selective cyclooxygenase-2 inhibitors. J. Med. Chem. 43, 2860-2870 (2000).
17. Kalgutkar, A.S. et al. Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors. Proc. Natl. Acad. Sci. USA 97, 925-930 (2000).
18. Zhou, Y. et al. Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Abeta42 by inhibiting Rho. Science 302, 1215-1217 (2003).
19. Miyata, K. et al. Rho-kinase is involved in macrophage-mediated formation of coronary vascular lesions in pigs in vivo. Arterioscler. Thromb. Vasc. Biol. 20, 2351-2358 (2000).
20. Ren, X.D. & Schwartz, M.A. Determination of GTP loading on Rho. Methods Enzymol. 325, 264-272 (2000).
21. Seiffert, D. et al. Presenilin-1 and -2 are molecular targets for gamma-secretase inhibitors. J. Biol. Chem. 275, 34086-34091 (2000).
22. Najib, J. Fenofibrate in the treatment of dyslipidemia: a review of the data as they relate to the new suprabioavailable tablet formulation. Clin. Ther. 24, 2022-2050 (2002).
23. Berger, J. et al. The four murine peroxisomal ABC-transporter genes differ in constitutive, inducible and developmental expression. Eur. J. Biochem. 265, 719-727 (1999).
24. Gan, X. et al. Dual mechanisms of ABCA1 regulation by geranylgeranyl pyrophosphate. J. Biol. Chem. 276, 48702-48708 (2001).
25. Magee, T. & Marshall, C. New insights into the interaction of Ras with the plasma membrane. Cell 98, 9-12 (1999).
26. Wahrle, S. et al. Cholesterol-Dependent gamma-Secretase Activity in Buoyant Cholesterol- Rich Membrane Microdomains. Neurobiol. Dis. 9, 11-23 (2002).
27. Vetrivel, K.S. et al. Association of gamma -secretase with lipid rafts in post-golgi and endosome membranes. J. Biol. Chem. 279, 44945-44954 (2004).
28. Keller, R.K. Squalene synthase inhibition alters metabolism of nonsterols in rat liver. Biochim. Biophys. Acta 1303, 169-179 (1996).
29. Liao, J.K. Isoprenoids as mediators of the biological effects of statins. J. Clin. Invest. 110, 285-288 (2002).
30. del Real, G. et al. Statins inhibit HIV-1 infection by down-regulating Rho activity. J. Exp. Med. 200, 541-547 (2004).
31. Wolozin, B., Kellman, W., Ruosseau, P., Celesia, G.G. & Siegel, G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3- methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57, 1439-1443 (2000).
32. Simons, M. et al. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc. Natl. Acad. Sci. USA 95, 6460-6464 (1998).
33. Refolo, L.M. et al. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. 8, 890-899 (2001).
34. Akiyama, H. et al. Inflammation and Alzheimer's disease. Neurobiol. Aging 21, 383-421 (2000).
35. Qin, W. et al. Cyclooxygenase (COX)-2 and COX-1 potentiate beta-amyloid peptide generation through mechanisms that involve gamma-secretase activity. J. Biol. Chem. 278, 50970-50977 (2003).
36. Xiang, Z. et al. Cyclooxygenase-2 promotes amyloid plaque deposition in a mouse model of Alzheimer's disease neuropathology. Gene Expr. 10, 271-278 (2002).
37. Davies, N.M., McLachlan, A.J., Day, R.O. & Williams, K.M. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin. Pharmacokinet. 38, 225-242 (2000).
38. Martin, B.K., Meinert, C.L. & Breitner, J.C. Double placebo design in a prevention trial for Alzheimer's disease. Control Clin. Trials 23, 93-99 (2002).
39. Koehne, C.H. & Dubois, R.N. COX-2 inhibition and colorectal cancer. Semin. Oncol. 31, 12-21 (2004).
40. Kammerl, M.C., Debler, J., Riegger, G.A. & Kramer, B.K. COX-2 inhibitors and risk of heart failure. Lancet 364, 1486-1487; author reply 1487 (2004).
41. Hardy, J. & Selkoe, D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356 (2002).
42. Murphy, M.P. et al. Presenilin 1 regulates pharmacologically distinct gamma-secretase activities. Implications for the role of presenilin in gamma -secretase cleavage. J. Biol. Chem. 275, 26277-26284 (2000).
43. Wang, R., Sweeney, D., Gandy, S.E. & Sisodia, S.S. The profile of soluble amyloid beta protein in cultured cell media. Detection and quantification of amyloid beta protein and variants by immunoprecipitation-mass spectrometry. J. Biol. Chem. 271, 31894-31902 (1996).
44. Anastasiadis, P.Z. et al. Inhibition of RhoA by p120 catenin. Nat. Cell Biol. 2, 637-644 (2000).
45. McLendon, C. et al. Cell-free assays for γ-secretase activity. FASEB J. 14, 2383-2386 (2000).
46. Hsiao, K. et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274, 99-102 (1996).
47. Kawarabayashi, T. et al. Age-dependent changes in brain, CSF, and plasma amyloid protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci. 21, 372-381 (2001).
48. Eckman, E.A., Watson, M., Marlow, L., Sambamurti, K. & Eckman, C.B. Alzheimer's disease beta-amyloid peptide is increased in mice deficient in endothelin-converting enzyme. J. Biol. Chem. 278, 2081-2084 (2003).